{"id":536254,"date":"2021-09-09T08:04:30","date_gmt":"2021-09-09T12:04:30","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/onconova-therapeutics-announces-participation-at-the-upcoming-h-c-wainwright-23rd-annual-global-investment-conference\/"},"modified":"2021-09-09T08:04:30","modified_gmt":"2021-09-09T12:04:30","slug":"onconova-therapeutics-announces-participation-at-the-upcoming-h-c-wainwright-23rd-annual-global-investment-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/onconova-therapeutics-announces-participation-at-the-upcoming-h-c-wainwright-23rd-annual-global-investment-conference\/","title":{"rendered":"Onconova Therapeutics Announces Participation\u00a0at the Upcoming H.C. Wainwright 23rd Annual Global Investment Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">NEWTOWN, Pa., Sept.  09, 2021  (GLOBE NEWSWIRE) &#8212; Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that the Company will be participating in the H.C. Wainwright 23<sup>rd<\/sup> Annual Global Investment Conference taking place virtually September 13-15, 2021.<\/p>\n<p align=\"justify\">A corporate overview, presented by Steven Fruchtman, M.D., President &amp; CEO of Onconova, will be available to conference participants beginning Monday, September 13<sup>th<\/sup> at 7:00 a.m. ET using the following link: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=xfbUmEMhZGkorTjNy5ihzDnd3TL8RqQO0DlZEL15d73oV_IQLVv-8I9sUzciTJQs9XP6SMgVV7jebvqPPkdvhJdfIS2ZTifiCHXv96XF2Xg_DC9lDNFi-Qk6CYLGVlLLEB9N9athC7uwCWpz8TvxQ6wD_ukCIHAWBrDSC2RBkFhYSQQ-j5dfYjIqYVuy-kJjuk37VgqGbO02r21H20F45w==\" rel=\"nofollow noopener\" target=\"_blank\">https:\/\/journey.ct.events\/view\/68e685c9-2525-4016-b704-7e93cf3d5f9b<\/a>.<\/p>\n<p align=\"justify\">Following the conference, the corporate overview will be available on the \u201c<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=yCQgylcppYNCWhohItxQsvm0DWJaG9kys-qq2XcYh6P-s_DKOVkOgk6A43ig8mY2yAx4dNfQ9-X8srwP4v8_x-mPaHb4G9h0vBFedFH4BGH29fCm1028SytA8OwQBN0mvmhrY4j4V5P0hE1DOUGTFw==\" rel=\"nofollow noopener\" target=\"_blank\">Corporate Events and Presentations<\/a>\u201d section of the Onconova website.<\/p>\n<p align=\"justify\">\n        <strong>About Onconova Therapeutics, Inc. <\/strong><br \/>\n        <br \/>Onconova Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer. The Company has proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation.<\/p>\n<p align=\"justify\">Onconova\u2019s novel, proprietary multi-kinase inhibitor ON 123300 is being evaluated in two separate and complementary Phase 1 dose-escalation and expansion studies. These trials are currently underway in the United States and China.<\/p>\n<p align=\"justify\">Onconova\u2019s product candidate rigosertib is being studied in an investigator-initiated study program, including in a dose-escalation and expansion Phase 1\/2a investigator-initiated study with oral rigosertib in combination with nivolumab for patients with KRAS+ non-small cell lung cancer.<\/p>\n<p align=\"justify\">For more information, please visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=mqXCGKiyMKU61g01OpGeUExuP1vDsriWyTo-v9QDOTSXmBLRUWiijTuti_WXc-fDjUYtbZKBlnW2d86yNuacATmkX_BhzDVuM-gaLMiH2dM4nP9xIrtbZJPtfg2AkOZZbY1Qcgq7fp1lTpeReJHn15ZQvaTVcUmJweeasHuwWNl8tVd7v3iRA1vcGvWAjq9xTsbggXdZgjRwDf2IyDxEHV9Lf3uspY1tqSuAcKb3kFY=\" rel=\"nofollow noopener\" target=\"_blank\">www.onconova.com<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>Forward-Looking Statements<\/strong><br \/>\n        <br \/>Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, and involve risks and uncertainties. These statements relate to Onconova\u2019s expectations regarding the timing of Onconova\u2019s and investigator-initiated clinical development and data presentation plans, and the mechanisms and indications for Onconova\u2019s product candidates. Onconova has attempted to identify forward-looking statements by terminology including &#8220;believes,&#8221; &#8220;estimates,&#8221; &#8220;anticipates,&#8221; &#8220;expects,&#8221; &#8220;plans,&#8221; &#8220;intends,&#8221; &#8220;may,&#8221; &#8220;could,&#8221; &#8220;might,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; \u201cpreliminary,\u201d &#8220;approximately&#8221; or other words that convey uncertainty of future events or outcomes. Although Onconova believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including the success and timing of Onconova&#8217;s clinical trials, investigator-initiated trials and regulatory agency and institutional review board approvals of protocols, Onconova\u2019s collaborations, the timing of the Company\u2019s annual stockholder meeting, market conditions and those discussed under the heading &#8220;Risk Factors&#8221; in Onconova&#8217;s most recent Annual Report on Form 10-K and quarterly reports on Form 10-Q. Any forward-looking statements contained in this release speak only as of its date. Onconova undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.<\/p>\n<p align=\"justify\">\n        <strong>Company Contact:<\/strong><br \/>\n        <br \/>Avi Oler<br \/>Onconova Therapeutics, Inc.<br \/>267-759-3680 <br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=1D5xHY38fctA3ufHiS7EbftMgBSQOd8PuYIGoPkuq1tWitc9lxgc7XPU5602rxvR8HIs3CioBN4HxxCHkV7M-g==\" rel=\"nofollow noopener\" target=\"_blank\">ir@onconova.us<\/a><br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=xfbUmEMhZGkorTjNy5ihzJ7n0OD0RwKKsACGl5wtshiPn6JwaNXMT3g28qpmV8H6KHZL707dlq3HTggEPyBnaNQSQwks3ZEkxy8NV5KjWgHuA2y5XDX-Iad99S65Gbcb\" rel=\"nofollow noopener\" target=\"_blank\">https:\/\/www.onconova.com\/contact\/<\/a><\/p>\n<p align=\"justify\">\n        <strong>Investor Contact:<\/strong><br \/>\n        <br \/>Bruce Mackle <br \/>LifeSci Advisors, LLC<br \/>646-889-1200<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=2-08AwrZb0rTRX65igFnXpZblmd89LtA6RI6Cn9G_3a-gNUP-7o-PIqthf_mF6UMxp5qHrRw1OD0Hj4Zb4I7Mfy5wLMNnLsqwBR0DeXxTOBnxkoRhwJiU8va7o85tnKV\" rel=\"nofollow noopener\" target=\"_blank\">bmackle@lifesciadvisors.com<\/a><\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyMjI5MyM0Mzk1MDM4IzIwMDU2MTU=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/NDIzMzk3OTUtN2U5Yy00YTRlLWJmZmUtZDhlZGUwMjg1ZDY3LTEwMTcxODg=\/tiny\/Onconova-Therapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>NEWTOWN, Pa., Sept. 09, 2021 (GLOBE NEWSWIRE) &#8212; Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that the Company will be participating in the H.C. Wainwright 23rd Annual Global Investment Conference taking place virtually September 13-15, 2021. A corporate overview, presented by Steven Fruchtman, M.D., President &amp; CEO of Onconova, will be available to conference participants beginning Monday, September 13th at 7:00 a.m. ET using the following link: https:\/\/journey.ct.events\/view\/68e685c9-2525-4016-b704-7e93cf3d5f9b. Following the conference, the corporate overview will be available on the \u201cCorporate Events and Presentations\u201d section of the Onconova website. About Onconova Therapeutics, Inc. Onconova Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing novel &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/onconova-therapeutics-announces-participation-at-the-upcoming-h-c-wainwright-23rd-annual-global-investment-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Onconova Therapeutics Announces Participation\u00a0at the Upcoming H.C. Wainwright 23rd Annual Global Investment Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-536254","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Onconova Therapeutics Announces Participation\u00a0at the Upcoming H.C. Wainwright 23rd Annual Global Investment Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/onconova-therapeutics-announces-participation-at-the-upcoming-h-c-wainwright-23rd-annual-global-investment-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Onconova Therapeutics Announces Participation\u00a0at the Upcoming H.C. Wainwright 23rd Annual Global Investment Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"NEWTOWN, Pa., Sept. 09, 2021 (GLOBE NEWSWIRE) &#8212; Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that the Company will be participating in the H.C. Wainwright 23rd Annual Global Investment Conference taking place virtually September 13-15, 2021. A corporate overview, presented by Steven Fruchtman, M.D., President &amp; CEO of Onconova, will be available to conference participants beginning Monday, September 13th at 7:00 a.m. ET using the following link: https:\/\/journey.ct.events\/view\/68e685c9-2525-4016-b704-7e93cf3d5f9b. Following the conference, the corporate overview will be available on the \u201cCorporate Events and Presentations\u201d section of the Onconova website. About Onconova Therapeutics, Inc. Onconova Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing novel &hellip; Continue reading &quot;Onconova Therapeutics Announces Participation\u00a0at the Upcoming H.C. Wainwright 23rd Annual Global Investment Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/onconova-therapeutics-announces-participation-at-the-upcoming-h-c-wainwright-23rd-annual-global-investment-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-09-09T12:04:30+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyMjI5MyM0Mzk1MDM4IzIwMDU2MTU=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/onconova-therapeutics-announces-participation-at-the-upcoming-h-c-wainwright-23rd-annual-global-investment-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/onconova-therapeutics-announces-participation-at-the-upcoming-h-c-wainwright-23rd-annual-global-investment-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Onconova Therapeutics Announces Participation\u00a0at the Upcoming H.C. Wainwright 23rd Annual Global Investment Conference\",\"datePublished\":\"2021-09-09T12:04:30+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/onconova-therapeutics-announces-participation-at-the-upcoming-h-c-wainwright-23rd-annual-global-investment-conference\\\/\"},\"wordCount\":544,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/onconova-therapeutics-announces-participation-at-the-upcoming-h-c-wainwright-23rd-annual-global-investment-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMyMjI5MyM0Mzk1MDM4IzIwMDU2MTU=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/onconova-therapeutics-announces-participation-at-the-upcoming-h-c-wainwright-23rd-annual-global-investment-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/onconova-therapeutics-announces-participation-at-the-upcoming-h-c-wainwright-23rd-annual-global-investment-conference\\\/\",\"name\":\"Onconova Therapeutics Announces Participation\u00a0at the Upcoming H.C. Wainwright 23rd Annual Global Investment Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/onconova-therapeutics-announces-participation-at-the-upcoming-h-c-wainwright-23rd-annual-global-investment-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/onconova-therapeutics-announces-participation-at-the-upcoming-h-c-wainwright-23rd-annual-global-investment-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMyMjI5MyM0Mzk1MDM4IzIwMDU2MTU=\",\"datePublished\":\"2021-09-09T12:04:30+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/onconova-therapeutics-announces-participation-at-the-upcoming-h-c-wainwright-23rd-annual-global-investment-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/onconova-therapeutics-announces-participation-at-the-upcoming-h-c-wainwright-23rd-annual-global-investment-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/onconova-therapeutics-announces-participation-at-the-upcoming-h-c-wainwright-23rd-annual-global-investment-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMyMjI5MyM0Mzk1MDM4IzIwMDU2MTU=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMyMjI5MyM0Mzk1MDM4IzIwMDU2MTU=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/onconova-therapeutics-announces-participation-at-the-upcoming-h-c-wainwright-23rd-annual-global-investment-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Onconova Therapeutics Announces Participation\u00a0at the Upcoming H.C. Wainwright 23rd Annual Global Investment Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Onconova Therapeutics Announces Participation\u00a0at the Upcoming H.C. Wainwright 23rd Annual Global Investment Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/onconova-therapeutics-announces-participation-at-the-upcoming-h-c-wainwright-23rd-annual-global-investment-conference\/","og_locale":"en_US","og_type":"article","og_title":"Onconova Therapeutics Announces Participation\u00a0at the Upcoming H.C. Wainwright 23rd Annual Global Investment Conference - Market Newsdesk","og_description":"NEWTOWN, Pa., Sept. 09, 2021 (GLOBE NEWSWIRE) &#8212; Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that the Company will be participating in the H.C. Wainwright 23rd Annual Global Investment Conference taking place virtually September 13-15, 2021. A corporate overview, presented by Steven Fruchtman, M.D., President &amp; CEO of Onconova, will be available to conference participants beginning Monday, September 13th at 7:00 a.m. ET using the following link: https:\/\/journey.ct.events\/view\/68e685c9-2525-4016-b704-7e93cf3d5f9b. Following the conference, the corporate overview will be available on the \u201cCorporate Events and Presentations\u201d section of the Onconova website. About Onconova Therapeutics, Inc. Onconova Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing novel &hellip; Continue reading \"Onconova Therapeutics Announces Participation\u00a0at the Upcoming H.C. Wainwright 23rd Annual Global Investment Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/onconova-therapeutics-announces-participation-at-the-upcoming-h-c-wainwright-23rd-annual-global-investment-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2021-09-09T12:04:30+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyMjI5MyM0Mzk1MDM4IzIwMDU2MTU=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/onconova-therapeutics-announces-participation-at-the-upcoming-h-c-wainwright-23rd-annual-global-investment-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/onconova-therapeutics-announces-participation-at-the-upcoming-h-c-wainwright-23rd-annual-global-investment-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Onconova Therapeutics Announces Participation\u00a0at the Upcoming H.C. Wainwright 23rd Annual Global Investment Conference","datePublished":"2021-09-09T12:04:30+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/onconova-therapeutics-announces-participation-at-the-upcoming-h-c-wainwright-23rd-annual-global-investment-conference\/"},"wordCount":544,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/onconova-therapeutics-announces-participation-at-the-upcoming-h-c-wainwright-23rd-annual-global-investment-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyMjI5MyM0Mzk1MDM4IzIwMDU2MTU=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/onconova-therapeutics-announces-participation-at-the-upcoming-h-c-wainwright-23rd-annual-global-investment-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/onconova-therapeutics-announces-participation-at-the-upcoming-h-c-wainwright-23rd-annual-global-investment-conference\/","name":"Onconova Therapeutics Announces Participation\u00a0at the Upcoming H.C. Wainwright 23rd Annual Global Investment Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/onconova-therapeutics-announces-participation-at-the-upcoming-h-c-wainwright-23rd-annual-global-investment-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/onconova-therapeutics-announces-participation-at-the-upcoming-h-c-wainwright-23rd-annual-global-investment-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyMjI5MyM0Mzk1MDM4IzIwMDU2MTU=","datePublished":"2021-09-09T12:04:30+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/onconova-therapeutics-announces-participation-at-the-upcoming-h-c-wainwright-23rd-annual-global-investment-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/onconova-therapeutics-announces-participation-at-the-upcoming-h-c-wainwright-23rd-annual-global-investment-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/onconova-therapeutics-announces-participation-at-the-upcoming-h-c-wainwright-23rd-annual-global-investment-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyMjI5MyM0Mzk1MDM4IzIwMDU2MTU=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyMjI5MyM0Mzk1MDM4IzIwMDU2MTU="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/onconova-therapeutics-announces-participation-at-the-upcoming-h-c-wainwright-23rd-annual-global-investment-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Onconova Therapeutics Announces Participation\u00a0at the Upcoming H.C. Wainwright 23rd Annual Global Investment Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/536254","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=536254"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/536254\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=536254"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=536254"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=536254"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}